论文部分内容阅读
[目的]探讨原发性肝癌(primary hepatic cancer,PHC)患者血清中肿瘤坏死因子(tumor necrosis factor,TNF-α)和甲胎蛋白(alpha-feta-protein,AFP)水平变化的临床意义。[方法]采用酶联免疫吸附法(Enzyme linkedimmunosorbent assay,ELISA)测定TNF-α,化学发光免疫法测定AFP。[结果]原发性肝癌患者血清TNF-α和AFP水平及阳性率均明显高于正常对照组及良性肝病组(P﹤0.05);PHC治疗后恶化或复发患者血清TNF-α和AFP水平比病情稳定组明显升高(P﹤0.01);联合检测的敏感性和诊断准确性均比单项检测高。[结论]联合检测TNF-α和AFP对PHC病情的观察、疗效的评价和预后的判断有重要价值。
[Objective] To investigate the clinical significance of serum tumor necrosis factor (TNF-α) and alpha-fetoprotein (AFP) levels in serum of patients with primary hepatic cancer (PHC). [Method] Enzyme linked immunosorbent assay (ELISA) was used to measure TNF-α, and chemiluminescence immunoassay was used to detect AFP. [Results] The serum levels of TNF-α and AFP in patients with primary liver cancer were significantly higher than those in the normal control group and benign liver disease group (P <0.05). The levels of serum TNF-α and AFP in the patients with PHC after the treatment of exacerbation or relapse Stable group was significantly higher (P <0.01); combined detection of sensitivity and diagnostic accuracy than the single test high. [Conclusion] The combined detection of TNF-α and AFP has an important value in the observation of PHC condition, evaluation of curative effect and judgment of prognosis.